Comments on: Pfizer Settles Whistleblower Case for $2.3 Billion http://blog.pharmexec.com/2009/09/02/pfizer-settles-whistleblower-case-for-23-billion/ The Business of Pharmaceuticals Wed, 08 Feb 2012 14:53:10 -0500 hourly 1 By: Daniel Haszard http://blog.pharmexec.com/2009/09/02/pfizer-settles-whistleblower-case-for-23-billion/comment-page-1/#comment-42711 Daniel Haszard Tue, 08 Sep 2009 08:28:55 +0000 http://blog.pharmexec.com/?p=1045#comment-42711 Eli Lilly has made $38 billion on Zyprexa and it was way oversold and caused diabetes and in some cases sudden death. Lilly still criminal on Zyprexa Please do a report on Lilly's (NOW up to $4.6 billion) Zyprexa setllement payout is being stonewalled. 8 Lilly employees who are supposed 'whistleblowers' are getting $ 10 million each the real victims like me are being ignored. I am a living example of Zyprexa gone/done wrong was given it 1996-2000 off-label for PTSD got sudden high blood sugar A1C 14.7 in January 2000.The stuff was worthless for my condition PTSD and cost me thousands in co-pays gave me diabetes. -- Daniel Haszard Eli Lilly has made $38 billion on Zyprexa and it was way oversold and caused diabetes and in some cases sudden death.

Lilly still criminal on Zyprexa
Please do a report on Lilly’s (NOW up to $4.6 billion) Zyprexa setllement payout is being stonewalled. 8 Lilly employees who are supposed ‘whistleblowers’ are getting $ 10 million each the real victims like me are being ignored.

I am a living example of Zyprexa gone/done wrong was given it 1996-2000 off-label for PTSD got sudden high blood sugar A1C 14.7 in January 2000.The stuff was worthless for my condition PTSD and cost me thousands in co-pays gave me diabetes.
–
Daniel Haszard

]]> By: Justice http://blog.pharmexec.com/2009/09/02/pfizer-settles-whistleblower-case-for-23-billion/comment-page-1/#comment-41969 Justice Thu, 03 Sep 2009 12:44:20 +0000 http://blog.pharmexec.com/?p=1045#comment-41969 The key to this case is that many of the off-label uses promoted were explicitly rejected by the FDA because of safety concerns. And what is unprecedented is not only the size of the penalty but the guilty plea to a felony, rather than simply a misdemeanor--something which essenially never happens in the context of pharma. We didn't need another such case. But I was not long ago on a panel is which a senior exec at Pfizer wondered out loud (yet again) why public trust in the industry has fallen so low. Bingo. The key to this case is that many of the off-label uses promoted were explicitly rejected by the FDA because of safety concerns. And what is unprecedented is not only the size of the penalty but the guilty plea to a felony, rather than simply a misdemeanor–something which essenially never happens in the context of pharma.

We didn’t need another such case. But I was not long ago on a panel is which a senior exec at Pfizer wondered out loud (yet again) why public trust in the industry has fallen so low.

Bingo.

]]> By: Daniel Haszard http://blog.pharmexec.com/2009/09/02/pfizer-settles-whistleblower-case-for-23-billion/comment-page-1/#comment-41804 Daniel Haszard Wed, 02 Sep 2009 19:44:51 +0000 http://blog.pharmexec.com/?p=1045#comment-41804 Eli Lilly's #1 cash cow Zyprexa drug sale $38 billion dollars so far,has a ten times greater risk of causing type 2 diabetes over the non-user of Zyprexa. So,here we have a conflict of interest that this same company also is a big profiteer of diabetes treatment. Daniel Haszard Eli Lilly’s #1 cash cow Zyprexa drug sale $38 billion dollars so far,has a ten times greater risk of causing type 2 diabetes over the non-user of Zyprexa.
So,here we have a conflict of interest that this same company also is a big profiteer of diabetes treatment.

Daniel Haszard

]]>